NetworkNewsBreaks Archive - Page 1817 of 1966

ThursdayOct 05, 2017 1:24 pm

NetworkNewsBreaks – SeeThruEquity Initiates Coverage on Cemtrex, Inc. (NASDAQ: CETX)

SeeThruEquity has initiated coverage and issued a price target of $6.45 on shares of Cemtrex, Inc.’s (NASDAQ: CETX) stock. Among other highlights, the analyst noted the company’s history of healthy growth through large accretive acquisitions undertaken by management. The company’s operations are split into two market segments: Electronics Manufacturing Services (EMS) and Industrial Products and Services (IPS). The company’s core EMS enables Cemtrex to offer a full end-to-end solution for original equipment manufacturer (OEM) partners to develop and introduce new products. The analyst believes Cemtrex has been overlooked on Wall Street and extremely undervalued in the industrial manufacturing and EMS…

ThursdayOct 05, 2017 11:48 am

NetworkNewsBreaks – Mizuho Securities Initiates Coverage with ‘Neutral’ Rating on FibroGen, Inc. (NASDAQ: FGEN)

Mizuho Securities USA LLC has initiated coverage with a ‘Neutral’ rating and price target of $61 on shares of FibroGen, Inc.’s (NASDAQ: FGEN) stock. Roxadustat is the company’s most advanced product candidate, currently in phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD). The analyst noted that the global collaboration deals FibroGen has in place position the company for a successful, global commercial launch of roxadustat upon NDA approval. Additionally, the analyst believes the company is nearing full valuation. For more information, visit www.fibrogen.com About FibroGen, Inc. FibroGen, Inc., headquartered in San Francisco, CA with…

ThursdayOct 05, 2017 11:46 am

NetworkNewsBreaks – Akebia Therapeutics, Inc. (NASDAQ: AKBA) Receives ‘Buy’ Rating from Mizuho Securities

Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $24 on shares of Akebia Therapeutics, Inc.’s (NASDAQ: AKBA) stock. The company’s lead product candidate, vadadustat, is currently in phase 3 trials for the treatment of anemia related to chronic kidney disease. Among other highlights, the analyst noted Akebia’s established partnerships with several important players in the renal market in preparation for commercialization of vadadustat. Mizuho analysts believe that Akebia is attractively valued considering the company’s lead product candidate, vadadustat, and the global collaboration deals in place. For more information, visit www.akebia.com About Akebia Therapeutics…

ThursdayOct 05, 2017 11:30 am

NetworkNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Subsidiary to Exhibit at Florida Restaurant & Lodging Show

Global financial technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE) this morning announced that its Aptito subsidiary will exhibit at the 2017 Florida Restaurant & Lodging Show scheduled to take place from October 11-13 at the Orange County Convention Center in Orlando, Florida. The event is expected to provide Aptito with added exposure as it unveils its most comprehensive Restaurant POS placement program to the market. “We are very excited to showcase our Aptito POS solution and kick off our North America road show to present our solution to merchants across the United States,” Vlad Sadovskiy, President of…

ThursdayOct 05, 2017 9:22 am

NetworkNewsBreaks – EVIO, Inc. (EVIO) Providing Accredited Testing Services to Oregon’s Industrial Hemp Sector

EVIO, Inc. (OTCQB: EVIO), a leading provider of cannabis analytical testing services, this morning announced that it is now prepared to offer accredited testing services to Oregon’s industrial hemp sector. “Industrial hemp is a rapidly growing industry with product applications ranging from foods like hemp seed, personal care products, textiles, and other industrial and consumer goods such as building materials,” Lori Glauser, COO of EVIO, stated in the news release. “In fact, hemp-based CBD oil alone is projected to reach $1 billion in sales by 2020, and, notably, big box stores like Target and Wal Mart are already offering the…

WednesdayOct 04, 2017 12:12 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on October 4, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: RGSE 224.76% – News: Inks exclusive license agreement with The Dow Chemical Company for the POWERHOUSE™ solar shingles system; hosting conference call today SQTX 42.86% – News: Completes $530M asset sale; FINRA authorizes symbol change INND 37.14% – News: Enters supply and distribution agreement with Blue-Gear Inc. for international rights of PSAP MTBC 32.59% – News: Enters contract with U.S. insurance carrier for EnrollmentPlus™ SaaS solution VBIO 18.94% – News: Reports biosynthesis breakthrough CATB…

WednesdayOct 04, 2017 11:48 am

NetworkNewsBreaks – SeeThruEquity Updates Coverage on Apricus Biosciences, Inc. (NASDAQ: APRI)

SeeThruEquity issued a company update and price target of $4.30 on shares of Apricus Biosciences, Inc.’s (NASDAQ: APRI) stock. The analyst noted that the company has several upcoming catalysts, including the FDA decision for its Vitaros™ New Drug Application (NDA) resubmission. The company has already received its PDUFA date, which is February 17, 2018. If approved, Vitaros™ could be commercialized in the multi-billion-dollar erectile dysfunction (ED) market by the end of 2018. For more information, visit www.Apricusbio.com About Apricus Biosciences, Inc. Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product…

WednesdayOct 04, 2017 10:30 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Provides Update on In Vitro Data Related to IGC-AD1

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided an update on compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model showing that, at varying concentrations of IGC-AD1, mitochondrial function is enhanced by 30-60 percent. “Based on our analysis of this and other previously announced compelling data, we are readying IGC-AD1 in a liquid formulation that will not cause inebriation,” Ram Mukunda, CEO of IGC, stated in the news release. “The initial commercialization will be through licensed medical cannabis dispensaries.” As…

WednesdayOct 04, 2017 10:04 am

NetworkNewsBreaks – PotNetwork Holding, Inc. (POTN) Names Dr. Richard Goulding as New Chief Executive Officer

PotNetwork Holding, Inc. (OTC: POTN) this morning announced, as part of its strategy to formulate, produce and market a spectrum of exclusive and diversely targeted cannabidiol blends, its appointment of Richard Goulding, MD as its new chief executive officer. Per the news release, Goulding is expected to play a key role in directing PotNetwork’s endeavors to develop targeted formulas designed to deliver results for a diverse spectrum of challenges that can be aided by cannabidiol. “We believe, based on studies and reports, that CBD can contribute impressively to quality of life in those that are able to benefit from its…

WednesdayOct 04, 2017 9:33 am

NetworkNewsBreaks – Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Enters Collaboration and Licensing Agreement with Canntab Therapeutics

Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) yesterday announced its entry into a collaboration and licensing agreement with Canntab Therapeutics Limited, developer of a patent-pending oral sustained release formulation for cannabinoids. Per the terms of the agreement, Emblem and Canntab will collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of this sustained release product, with Emblem receiving the exclusive right in Canada to Canntab’s patents and know-how for the purpose of developing and commercializing the innovative product under the Emblem brand. Manufacture of the sustained release product is expected to be completed by Emblem or Canntab following…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks